Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)

(2014) Lecia A. M. Brown et al.   PLoS One

The Veterans Aging Cohort Study Index is Associated With Concurrent Risk for Neurocognitive Impairment

(2013) María J. Marquine et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

8-Hydroxy-efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes

(2013) Maria Brandmann et al.   NEUROCHEMICAL RESEARCH

Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study

(2013) José R. Santos et al.   PLoS One

Improved Neuropsychological and Neurological Functioning Across Three Antiretroviral Regimens in Diverse Resource-Limited Settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study

(2012) K. Robertson et al.   CLINICAL INFECTIOUS DISEASES

Intra-Individual Variability Across Neurocognitive Domains in Chronic Hepatitis C Infection: Elevated Dispersion is Associated With Serostatus and Unemployment Risk

(2012) Erin E. Morgan et al.   CLINICAL NEUROPSYCHOLOGIST

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy

(2012) Torsak Bunupuradah et al.   JOURNAL OF NEUROVIROLOGY

Antiretroviral neurotoxicity

(2012) Kevin Robertson et al.   JOURNAL OF NEUROVIROLOGY

Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation

(2012) Lucy J. Garvey et al.   PLoS One

Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents

(2011) Alan Winston et al.   AIDS

Screening for Cognitive Impairment in Human Immunodeficiency Virus

(2011) V. Valcour et al.   CLINICAL INFECTIOUS DISEASES

Hepatitis C Virus Infects the Endothelial Cells of the Blood-Brain Barrier

(2011) Nicola F. Fletcher et al.   GASTROENTEROLOGY

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS

(2011) Pornpun Vivithanaporn et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

(2011) N. Ciccarelli et al.   NEUROLOGY

HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon

(2010) Georgette D Kanmogne et al.   BMC Neurology

Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection

(2010) A. Thiyagarajan et al.   CLINICAL MICROBIOLOGY AND INFECTION

Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)

(2010) David B. Clifford et al.   HIV CLINICAL TRIALS

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

(2010) B. M. Best et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY

The Aging of Human-Immunodeficiency-Virus-Associated Neurocognitive Disorders

(2009) Tsuneya Ikezu   Journal of Neuroimmune Pharmacology

Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?

(2009) A. Winston et al.   JOURNAL OF VIRAL HEPATITIS